Thalidomide may impede cell migration in primates by down-regulating integrin β-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis
- 31 August 1997
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 49 (2) , 123-131
- https://doi.org/10.1016/s0306-9877(97)90217-6
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomideLife Sciences, 1995
- Thalidomide and the immune system 3. simultaneous up- and down-regulation of different integrin receptors on human white blood cellsLife Sciences, 1994
- Thalidomide and the immune system. 4. Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primatesLife Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virusJournal of the American Academy of Dermatology, 1993
- RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectinExperimental Cell Research, 1992
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Cachectin: More Than a Tumor Necrosis FactorNew England Journal of Medicine, 1987
- Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditionsJournal of the American Academy of Dermatology, 1982